Home / Market News / $CTNM
fiscal.ai Corporate Catalyst Impact 55/100 ● positive

Contineum Therapeutics, Inc. 12-Month Price Target Adjusted to $21.43

Nov 5, 2026, 2:14 PM UTC · Primary ticker $CTNM

Contineum Therapeutics' average 12-month price target has been slightly lowered from $22.14 to $21.43 by analysts. Despite this minor adjustment, the consensus rating remains a 'Buy,' indicating continued positive sentiment among covering analysts.

Contineum Therapeutics, Inc. (CTNM) has seen a slight downward revision in its average 12-month price target from $22.14 to $21.43, based on estimates from seven analysts. While this represents a minor negative adjustment, the overall sentiment remains positive, with eight covering analysts maintaining a 'Buy' consensus rating (six buy, two hold). This indicates that while some analysts may have slightly tempered their expectations, the fundamental outlook for the company is still viewed favorably. For traders, this is a relatively minor update, suggesting limited short-term impact, but it's worth noting the slight dip in price targets. The key opportunity lies in whether the company can outperform these revised expectations or if further downward revisions signal a deteriorating outlook.

$CTNM neutral Analyst price target adjustment
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.